Substance for regulating immune function of atrophic gastritis and preparation and application of substance

Abstract

The invention discloses a substance for regulating the immune function of atrophic gastritis and a preparation and application of the substance. The substance for regulating the immune function of theatrophic gastritis is one or more of new ligustilide, oleanolic acid, atractylenolide I, eucalyptol, isorhamnetin and coptisine. The preparation is a tablet, a capsule, a pill, an injection, a sustained-release agent, a controlled-release agent, powder or an oral liquid preparation prepared by adding pharmaceutically acceptable auxiliary materials into the substance for regulating the immune function of atrophic gastritis. The substance for regulating the immune function of the atrophic gastritis is applied to preparation of a medicine for treating low immune function of the atrophic gastritis. According to the invention, network pharmacology calculation prediction and experimental verification identify components capable of regulating atrophic gastritis accompanied by low immune functionin a Chinese patent medicine, Muoluo Dan. In-vitro verification experiments show that the components can improve immune related indexes such as CD40, CD44, TRAF6 and the like of atrophic gastritis accompanied by low immune function.

Description

technical field [0001] The invention belongs to the technical field of medicine, and in particular relates to a substance for regulating the immune function of atrophic gastritis, its preparation and application. Background technique [0002] Atrophic gastritis is a common disease of the digestive system characterized by the reduction or disappearance of the number of intrinsic glands in the gastric mucosal epithelium, or with fibrous replacement and intestinal glandular metaplasia. Its pathogenesis involves changes in cell proliferation, apoptosis, cell differentiation, immunity, metabolism, and digestion. Atrophic gastritis with low immune function is a common clinical subgroup, and these patients usually show low cellular and humoral immunity. The levels of serum IgG, IgA, IgM and other immunoglobulins were significantly decreased in patients with chronic atrophic gastritis with low immune function, and the levels of CD3+T cells and CD4+T cells were significantly decreas...

AI Technical Summary

Problems solved by technology

[0079] In order to solve the above-mentioned technical problems, the present invention aims at the problem that the effective substance basis of Moluodan in the treatment of atrophic gastritis with low immune function is not clear. Through network pharmacology calculation analysis and experimental verification, it is identified that Moluodan is especially effective in treating atrophic gastritis. It is an ingredient associated with low immune function, and it has been verified through experiments that this ingredient can improve the objective index of low immune function in atrophic gastritis

Images